Ignyta announced results of phase 1 trial and start of phase 2 trial

As of September 30, 2015.

Two Phase 1 results:

Total of 92 patients

18 patients met phase 2 eligibility requirements and took phase 2 dose level

Among 18 patients 72% respose rate. 4 of 6 (66%) ALK+ patients responded. Drug also targets 3-4 other mutations and they are testing it on cancers from several different tissue types.

Phase 2 trial will be multinational and at over 100 testing locations. Must have one of the targeted mutations. Must be ALK inhibitors naive.

More details can be found at:  http://www.businesswire.com/news/home/20150930005382/en/Ignyta-Announces-Initiation-STARTRK-2-Phase-2-Clinical#.Vgv1dNT3aK0

This entry was posted in Lung cancer, Research, RXDX-101 - entrectinib - by Ignyta, Side Effects. Bookmark the permalink.

Leave a Reply